This article reviews the cholinergic changes in Parkinson’s disease and dementia (PDD) and dementia with Lewy bodies (DLB), their potential clinical implications, and the available evidence for cholinesterase inhibitors in the treatment of PDD and DLB. Marked neuronal loss of cholinergic nuclei, reduced cholinergic markers in the neocortex, hippocampus, and selected thalamic nuclei, and receptor changes have been reported. One large and 2 small placebo-controlled trials and nearly 20 open-label studies suggest that cholinesterase inhibitors have a positive effect on cognition, psychiatric symptoms, and global function in patients with DLB and PDD. The treatment is well tolerated in most patients without any apparent worsening of extrapyramidal motor features. Given the high risk of severe sensitivity reactions and increased risk of cerebrovascular incidents during treatment with neuroleptics, more clinical trials of cholinesterase inhibitors are encouraged to establish their precise role in DLB and PDD. (J Geriatr Psychiatry Neurol 2004; 17:164-171)
1. Whitehouse PJ, Hedreen JC, White CL 3rd, Price DL. Basal fore-brain neurons in the dementia of Parkinson disease. Ann Neurol1983; 13:243-248.
2.
2. Lippa CF, Smith TW, Perry E.Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology. J Neural Transm1999; 106:525-535.
3.
3. Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry1985; 48:413-421.
4.
4. Samuel W, Alford M, Hofstetter CR, Hansen L.Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol1997; 56:499-508.
5.
5. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology1996; 47:1113-1124.
6.
6. Perry EK, Irving D, Kerwin JM, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord1993; 7:69-79.
7.
7. Aubert I, Araujo DM, Cecyre D, et al. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer’s and Parkinson’s diseases. J Neurochem1992; 58:529-541.
8.
8. Tiraboschi P, Hansen LA, Alford M, et al. The decline in synapses and cholinergic activity is asynchronous in Alzheimer’s disease. Neurology2000; 55:1278-1283.
9.
9. Tiraboschi P, Hansen LA, Alford M, et al. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry2002; 59:946-951.
10.
10. Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol1996; 40:399-410.
11.
11. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol2003; 60:1745-1748.
12.
12. Jellinger K.The pedunculopontine nucleus in Parkinson’s dis-ease, progressive supranuclear palsy and Alzheimer’s disease. J Neurol Neurosurg Psychiatry1988; 51:540-543.
13.
13. Boeve BF, Silber MH, Parisi JE, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology2003; 61:40-45.
14.
14. Ziabreva I, Ballard CL, Aarsland D, et al. Cortical and thalamic cholinergic activity in Lewy body disease in relation to dementia and parkinsonism. Presented at: MDS-Conference, Rome, Italy, 2004.
15.
15. Perry EK, Marshall E, Kerwin J, et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem1990; 55:1454-1456.
16.
16. Ballard C, Piggott M, Johnson M, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol2000; 48:868-876.
17.
17. Court JA, Piggott MA, Lloyd S, et al. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s dis-ease and in relation to neuroleptic medication. Neuroscience2000; 98:79-87.
18.
18. Burn DJ, Rowan EN, Minett T, et al. Extrapyramidal features in Parkinson’s disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord2003; 18:884-889.
19.
19. Duda JE. Pathology and neurotransmitter abnormalities of dementia with lewy bodies. Dement Geriatr Cogn Disord2004; 17(suppl 1):3-14.
20.
20. Ballard CG. Advances in the treatment of Alzheimer’s disease: benefits of dual cholinesterase inhibition. Eur Neurol2002; 47:64-70.
21.
21. O’Brien KK, Saxby BK, Ballard CG, et al. Regulation of attention and response to therapy in dementia by butyryl-cholinesterase. Pharmacogenetics2003; 13:231-239.
22.
22. Perry E, McKeith I, Ballard C.Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology2003; 60:1852-2853.
23.
23. Sirvio J, Soininen HS, Kutvonen R, et al. Acetyl-and butyryl-cholinesterase activity in the cerebrospinal fluid of patients with Parkinson’s disease. J Neurol Sci1987; 81:273-279.
24.
24. Weinstock M.Selectivity of cholinesterase inhibition. CNS Drugs1999; 12:307-323.
25.
25. Reid RT, Sabbagh MN, Corey-Bloom J, et al. Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer’s disease. Neurobiol Aging2000; 21:741-746.
26.
26. Pimlott SL, Piggott M, Owens J, et al. Nicotinic acetylcholine receptor distribution in Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology2004; 29:108-116.
27.
27. Court JA, Ballard CG, Piggott MA, et al. Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies. Pharmacol Biochem Behav2001; 70:571-579.
28.
28. Ballard CG, Court JA, Piggott M, et al. Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex. Conscious Cogn2002; 11:461-474.
29.
29. Fagerstrom KO, Pomerleau O, Giordani B, Stelson F.Nicotine may relieve symptoms of Parkinson’s disease. Psychopharmacology (Berl)1994; 116:117-119.
30.
30. Kelton MC, Kahn HJ, Conrath CL, Newhouse PA. The effects of nicotine on Parkinson’s disease. Brain Cogn2000; 43:274-282.
31.
31. Vieregge A, Sieberer M, Jacobs H, et al. Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology2001; 57:1032-1035.
32.
32. Hellstrom-Lindahl E, Moore H, Nordberg A.Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. J Neurochem2000; 74:777-784.
33.
33. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet2000; 356:2031-2036.
34.
34. Aarsland D, Laake K, Larsen JP, Janvin C.Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry2002; 72:708-712.
35.
35. Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry2004; 19:1-8.
36.
36. Herrmann M, Aarsland D, Albanese A, et al. EXPRESS: a prospective, placebo-controlled study of rivastigmine in Parkinson’s disease dementia. Presented at: 6th International AD/PD Conference, Sevilla, Spain, 2003.
37.
37. Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol Sci2002; 23:41-43.
38.
38. Hutchinson M, Fazzini E.Cholinesterase inhibition in Parkinson’s disease. J Neurol Neurosurg Psychiatry1996; 61:324-325.
39.
39. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int J Geriatr Psychiatry2003; 18:937-941.
40.
40. Grace J, Daniel S, Stevens T, et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr2001; 13:199-205.
41.
41. Querfurth HW, Allam GJ, Geffroy MA, et al. Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial. Dement Geriatr Cogn Disord2000; 11:314-321.
42.
42. Edwards KR, Hershey L, Wray L, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Geriatr Cogn Disord2004; 17(suppl 1):40-48.
43.
43. Shea C, MacKnight C, Rockwood K.Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr1998; 10:229-238.
44.
44. McKeith IG, Grace JB, Walker Z, et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry2000; 15:387-392.
45.
45. Onofrj M, Thomas A.Severe worsening of parkinsonism in Lewy body dementia due to donepezil. Neurology2003; 61:1452-1452.
46.
46. Burton EJ, McKeith IG, Burn DJ, et al. Cerebral atrophy in Parkinson’s disease with and without dementia: a comparison with Alzheimer’s disease, dementia with Lewy bodies and controls. Brain2004; 127:791-800.
47.
47. Piggott MA, Owens J, O’Brien J, et al. Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease. J Chem Neuroanat2003; 25:161-173.
48.
48. Samuel W, Caligiuri M, Galasko D, et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry2000; 15:794-802.
49.
49. Levy R, Eagger S, Griffiths M, et al. Lewy bodies and response to tacrine in Alzheimer’s disease. Lancet1994; 343:176-176.
50.
50. Perry EK, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson’s disease related to antimuscarinic drugs. Ann Neurol2003; 54:235-238.
51.
51. Minett TS, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia. Int J Geriatr Psychiatry2003; 18:988-993.
52.
52. Kulisevsky J, Garcia-Sanchez C, Berthier ML, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson’s disease: a two-year follow-up study of previously untreated patients. Mov Disord2000; 15:613-626.
53.
53. Goetz CG, et al. Management of Parkinson’s disease. Mov Disord2002; 17(suppl 4).
54.
54. McKeith I, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. Br Med J1992; 305:673-678.
55.
55. Aarsland D, Perry R, Larsen JP, et al. High frequency of marked neuroleptic sensitivity in PD, PDD as well as in dementia with Lewy bodies with typical and atypical neuroleptic. Presented at: 3rd International Workshop on Dementia with Lewy Bodies and Parkinson’s Disease Dementia (DLB/PDD), Newcastle upon Tyne, UK, 2003.
56.
56. Kurita A, Ochiai Y, Kono Y, et al. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson’s disease. J Geriatr Psychiatry Neurol2003; 16:184-188.
57.
57. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord2001; 16:1171-1174.
58.
58. Bergman J, Lerner V.Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin Neuropharmacol2002; 25:107-110.
59.
59. Bullock R, Cameron A.Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr Med Res Opin2002; 18:258-264.
60.
60. Giladi N, Shabtai H, Gurevich T, et al. Rivastigmine (Exelon) for dementia in patients with Parkinson’s disease. Acta Neurol Scand2003; 108:368-373.
61.
61. Werber EA, Rabey JM. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson’s disease and dementia. J Neural Transm2001; 108:1319-1325.
62.
62. Wesnes KA, McKeith IG, Ferrara R, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord2002; 13:183-192.
63.
63. Lebert F, Pasquier F, Souliez L, Petit H.Tacrine efficacy in Lewy body dementia. Int J Geriatr Psychiatry1998; 13:516-519.
64.
64. Maclean LE, Collins CC, Byrne EJ. Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep. Int Psychogeriatr2001; 13:277-288.
